Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Pooled it
- A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.Breast cancer research and treatment · 2023Trial
- An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial).Annals of oncology : official journal of the European Society for Medical Oncology · 2019Trial
- Mitochondria-mediated anticancer effects of two previously characterized COX-2 inhibitors in hepatocellular carcinoma.Molecular and cellular biochemistry · 2026Article
- Bioinformatics analysis of TRPV1 expression and its role in hepatocellular carcinoma prognosis.Discover oncology · 2026Article
- Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients.Therapeutic advances in medical oncology · 2026Article
- Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Hepatocellular Carcinoma: A Review of Emerging Applications for Locoregional Therapy.Bioengineering (Basel, Switzerland) · 2025Review
- Review
- Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.Cancer biology & medicine · 2023Review
- Review
- CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Generation ofActa pharmaceutica Sinica. B · 2022Article
- Identification of CD105 (endoglin) as novel risk marker in CLL.Annals of hematology · 2022Article
- Curcuminoids Inhibit Angiogenic Behaviors of Human Umbilical Vein Endothelial Cells via Endoglin/Smad1 Signaling.International journal of molecular sciences · 2022Article
- Targets of immunotherapy for hepatocellular carcinoma: An update.World journal of hepatology · 2022Review
- Recent advances in systemic therapy for hepatocellular carcinoma.Biomarker research · 2022Review
- TGF-β superfamily co-receptors in cancer.Developmental dynamics : an official publication of the American Association of Anatomists · 2022Review
- Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology.Oncoimmunology · 2022Article
- Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook.Journal of hepatocellular carcinoma · 2022Review
- Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study.Translational vision science & technology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.